Savings from lower insurance costs of growth hormone drugs not passed on to patients

Increasingly aggressive insurance strategies have lowered the total costs and insurance costs of growth hormone drugs, but those savings are not being passed on to patients, according to new research to be presented Sunday at ENDO 2019, the Endocrine Society’s annual meeting in New Orleans, La.

From https://www.news-medical.net/news/20190325/Savings-from-lower-insurance-costs-of-growth-hormone-drug-not-passed-on-to-patients.aspx

from
https://healthnews010.wordpress.com/2019/03/25/savings-from-lower-insurance-costs-of-growth-hormone-drugs-not-passed-on-to-patients/

from https://karlfletcher.blogspot.com/2019/03/savings-from-lower-insurance-costs-of.html

from
https://karlfletcher1.tumblr.com/post/183696507928

From https://davidrawlins1.blogspot.com/2019/03/savings-from-lower-insurance-costs-of.html

from
https://davidrawlins1.wordpress.com/2019/03/25/savings-from-lower-insurance-costs-of-growth-hormone-drugs-not-passed-on-to-patients/